AstraZeneca considers moving listing to US, the Times reports

(Reuters) -AstraZeneca is contemplating transferring its inventory market itemizing from London, the place it’s the trade’s most respected firm, to america, the Instances reported on Tuesday, citing a number of sources.

Any such transfer could be a significant blow to the UK inventory market, which has seen a string of delistings and missed out on some main preliminary public choices in latest months.

It will additionally attraction to President Donald Trump’s hopes of drawing funding to america, whilst his commerce coverage has created uncertainty for international firms. He has threatened to impose 25% tariffs on pharmaceutical imports.

CEO Pascal Soriot has privately expressed a desire to shift AstraZeneca’s itemizing on a number of events and has additionally mentioned relocating the corporate’s domicile, the Instances mentioned.

AstraZeneca, which has a market worth of about 156 billion kilos ($213 billion), declined to remark.

The corporate has for years criticised the UK enterprise funding local weather. In January it scrapped plans to speculate 450 million kilos in its vaccine manufacturing plant in northern England, citing a lower in authorities assist.

In the meantime, the corporate has been strengthening its ties to the U.S. over the previous 12 months, each when it comes to manufacturing funding and contacts with buyers and lawmakers.

Its U.S. plans embody a $3.5 billion funding in home manufacturing by the tip of 2026. The corporate earlier this 12 months additionally rejoined the main U.S. drug foyer group, roughly two years after leaving it.

The U.S. can be AstraZeneca’s largest market, accounting for about 42% of its income within the first quarter of this 12 months.

Soriot may face opposition from some board members and the UK authorities if he pursues the transfer, in keeping with the Instances report, which added that the federal government had not been knowledgeable.

London-listed shares in AstraZeneca final traded up 2.8% at 10,328 pence.

(Reporting by Mrinalika Roy, Aatrayee Chatterjee and Shanima A in Bengaluru, Patrick Wingrove in New York, and Maggie Fick in London; Enhancing by Leroy Leo and Mark Potter)